Panacea equips innovators in the life science and healthcare domains with an all-inclusive R&D and commercialisation turnkey package paired with capital to help translate research high quality science into investable assets and thriving companies. Since its genesis at the University of Oxford in 2015, Panacea has helped some of the world’s leading scientists, entrepreneurs and clinicians building over 250 companies thus far that offer cutting-edge technologies. Our top performing 55 companies have a value of over £600m, with several exits realised, including the recent acquisition of DJS antibodies by AbbVie for $255m.

We are currently recruiting for the Onco Stars SS23 (Oncology) and LifeSci Stars SS23 (Life Sciences & Diagnostics) programmes which will take place in June-July. We welcome early-stage ideas that have the potential to impact human health.
LifeSci Stars is run in partnership with Bio-Rad Laboratories. Specific areas of interest for this programme are innovative products and technologies for life science research, food safety and clinical diagnostics. In the area of life science research: single-cell biology, cell & gene therapy, proteomics, protein characterisation and purification technologies. In clinical diagnostics: new biomarkers, novel detection methods for proteins and nucleic acids, and new approaches for molecular diagnostics.

OncoStars is run in partnership with Cancer Research UK. Specific areas of interest for this programme are innovative products and technologies in the diagnostics, treatment and prevention of cancer.

Those programmes are equity-free, free of charge and benefits from the support of one of the industry’s most well-established Mentors network, including Baillie Gifford, AstraZeneca, Bio-Rad, McKinsey & Co, J A Kemp, as well as research funding bodies and charities, including Innovate UK, Cancer Research UK and others.

The aim of those programmes is to help all clinicians and scientists to understand the research translation ecosystem, think about how their ideas and discoveries could be commercialised, and plan their work with translational potential in mind. Those four-week, structured initiatives are aimed at clinicians and scientists with little or no previous experience of research translation, and whose work is not currently at a stage where there is clear commercial potential.

Our next application deadline is Sunday 21st May 2023 at 11:59pm GMT. The best companies will be offered a place in our more advanced programme, Develop AW23/24 at the end of which they will have the opportunity to win a non-dilutive prize worth £100k!